The filing for a mixed shelf offering indicates Benitec Biopharma's intention to raise capital, which can be used for strategic initiatives. This is generally seen as a positive move for growth-oriented companies, as it provides financial flexibility. However, it may also lead to dilution of existing shares, which is a potential downside.